Gene: EGFR ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1057519847
rs1057519847
EGFR
0.800 GeneticVariation BEFREE We treated a 38-year-old patient with NSCLC who carried the EGFR L858R mutation. 30127621

2018
dbSNP: rs1057519848
rs1057519848
EGFR
0.800 GeneticVariation BEFREE We treated a 38-year-old patient with NSCLC who carried the EGFR L858R mutation. 30127621

2018
dbSNP: rs121434568
rs121434568
EGFR
0.800 GeneticVariation BEFREE We treated a 38-year-old patient with NSCLC who carried the EGFR L858R mutation. 30127621

2018
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We reviewed the medical records of consecutive patients with advanced NSCLC harboring EGFR-activating mutations and secondary T790M, who had undergone osimertinib re-administration to treat acquired resistance. 31097094

2019
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M. 26943236

2016
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We retrospectively investigated 135 patients with advanced NSCLC who obtained progression-free survival (PFS) after EGFR-TKI for >6 months for their EGFR sensitive mutations and T790M mutation in matched pre- and post-TKI plasma samples, using denaturing high-performance liquid chromatography (DHPLC), amplification refractory mutation system (ARMS), and digital-PCR (D-PCR). 25405807

2014
dbSNP: rs1057519847
rs1057519847
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. 25990507

2015
dbSNP: rs1057519848
rs1057519848
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. 25990507

2015
dbSNP: rs121434568
rs121434568
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects of second-line platinum combination chemotherapy after first-line gefitinib treatment in NSCLC patients harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation) at five institutions. 25990507

2015
dbSNP: rs1057519847
rs1057519847
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation). 29737372

2018
dbSNP: rs1057519848
rs1057519848
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation). 29737372

2018
dbSNP: rs121434568
rs121434568
EGFR
0.800 GeneticVariation BEFREE We retrospectively evaluated the clinical effects and safety profiles of second-line cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with NSCLC harboring sensitive EGFR mutations (exon 19 deletion/exon 21 L858R mutation). 29737372

2018
dbSNP: rs1057519847
rs1057519847
EGFR
0.800 GeneticVariation BEFREE We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation). 19777258

2010
dbSNP: rs1057519848
rs1057519848
EGFR
0.800 GeneticVariation BEFREE We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation). 19777258

2010
dbSNP: rs121434568
rs121434568
EGFR
0.800 GeneticVariation BEFREE We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation). 19777258

2010
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We retrospectively analyzed 74 EGFR T790M mutant NSCLC patients treated with osimertinib. 29775809

2018
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We retrospectively analyzed 50 pre-treated EGFR T790M-positive NSCLC patients treated with osimertinib at seven Swiss centers. 30885336

2019
dbSNP: rs121913465
rs121913465
EGFR ; EGFR-AS1
T 0.740 CausalMutation CLINVAR We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib. 20522446

2010
dbSNP: rs121913465
rs121913465
EGFR ; EGFR-AS1
0.740 GeneticVariation BEFREE We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib. 20522446

2010
dbSNP: rs397517108
rs397517108
EGFR ; EGFR-AS1
0.740 GeneticVariation BEFREE We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib. 20522446

2010
dbSNP: rs1057519847
rs1057519847
EGFR
0.800 GeneticVariation BEFREE We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R. 31571928

2019
dbSNP: rs1057519848
rs1057519848
EGFR
0.800 GeneticVariation BEFREE We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R. 31571928

2019
dbSNP: rs121434568
rs121434568
EGFR
0.800 GeneticVariation BEFREE We report three cases that were definitively diagnosed as LM from NSCLC with a mutation of epidermal growth factor receptor (<i>EGFR</i>) L858R. 31571928

2019
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We report the first case, to our knowledge, of a patient affected by metastatic EGFR-mutated NSCLC with T790M-driven acquired TKI resistance who obtained a significant response to afatinib. 24675505

2014
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.100 GeneticVariation BEFREE We report here that an non-small-cell lung cancer patient with the EGFR mutant T790M showed a programmed cell death ligand 1 (PD-L1) expression level that increased from <25% to >90% after eighth-line osimertinib therapy. 30237726

2018